Claude identifies a CRISPR-like enzyme system in phages
Anthropic says Claude agents found an uncharacterized reverse-transcriptase system after screening 200,000 proteins and guiding lab validation.
What happened
Anthropic said its new life-sciences group used Claude agents to identify a previously uncharacterized enzyme system in bacteriophages. The system, called array-associated reverse transcriptases (ARTs), combines a reverse-transcriptase gene, a neighboring accessory gene and a long array of repeating DNA sequences.
The finding emerged from a 21-hour search involving roughly 950 agents and 210 million tokens. Claude agents surveyed more than 200,000 reverse transcriptases, selected 3,500 unusual candidate systems and narrowed them to 20 for closer analysis. One agent noticed a repeat pattern beside an unusual reverse transcriptase that had not previously been recognized as part of a functional system.
Anthropic’s scientists then performed laboratory tests. Early results indicate that the repeat array is transcribed into multiple short RNAs, a feature that gives the system a superficial resemblance to programmable CRISPR biology. The company does not yet know what ART does, and its possible usefulness as a biotechnology tool remains unproven.
Why it matters
The important claim is not that Claude has already created a new gene-editing platform. It is that a model-led workflow moved from large-scale sequence mining to a testable biological hypothesis, while human researchers retained responsibility for experiments. Anthropic says the lab works at BSL-1 and BSL-2 levels and does not handle human pathogens.
If ART’s function is confirmed, the episode could become an early example of AI helping scientists find overlooked molecular systems rather than merely summarizing published knowledge. For now, the discovery is best treated as a credible lead: the mechanism, programmability and practical value still await independent characterization.